markets · · proactiveinvestors.com
IXICO expects 28% revenue growth as orders accelerate
IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), the neuroscience imaging and biomarker analytics company, expects annual revenue to rise 28% to £8.3 million, exceeding its upgraded guidance after an acceleration in analysis orders during the final quarter. The AIM-listed group reported revenue of £6.5 million for the previous financial year and had raised its 2026 revenue forecast from £7.5 million to £8 million in July.
IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), the neuroscience imaging and biomarker analytics company, expects annual revenue to rise 28% to £8.3 million, exceeding its upgraded guidance after an acceleration in analysis orders during the final quarter. The AIM-listed group reported revenue of £6.5 million for the previous financial year and had raised its 2026 revenue forecast from £7.5 million to £8 million in July.
- #PHYOF